[go: up one dir, main page]

CL2012001547A1 - Anticuerpo ligante de csf-1r humano; composicion farmaceutica que lo comprende; acido nucleico que lo codifica; vector de expresion recombinante; celula procariotica o eucariotica transformada; metodo de produccion; y su uso para tratar cancer. - Google Patents

Anticuerpo ligante de csf-1r humano; composicion farmaceutica que lo comprende; acido nucleico que lo codifica; vector de expresion recombinante; celula procariotica o eucariotica transformada; metodo de produccion; y su uso para tratar cancer.

Info

Publication number
CL2012001547A1
CL2012001547A1 CL2012001547A CL2012001547A CL2012001547A1 CL 2012001547 A1 CL2012001547 A1 CL 2012001547A1 CL 2012001547 A CL2012001547 A CL 2012001547A CL 2012001547 A CL2012001547 A CL 2012001547A CL 2012001547 A1 CL2012001547 A1 CL 2012001547A1
Authority
CL
Chile
Prior art keywords
encodes
nucleic acid
pharmaceutical composition
production
expression vector
Prior art date
Application number
CL2012001547A
Other languages
English (en)
Inventor
Georg Fertig
Nikolaos Dimoudis
Klaus Kaluza
Alexander Fidler
Marlene Pickl
Carola Ries
Stefan Seeber
Lanzendoerf
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43735019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001547(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2012001547A1 publication Critical patent/CL2012001547A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL2012001547A 2009-12-10 2012-06-08 Anticuerpo ligante de csf-1r humano; composicion farmaceutica que lo comprende; acido nucleico que lo codifica; vector de expresion recombinante; celula procariotica o eucariotica transformada; metodo de produccion; y su uso para tratar cancer. CL2012001547A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09015310 2009-12-10
EP10173407 2010-08-19

Publications (1)

Publication Number Publication Date
CL2012001547A1 true CL2012001547A1 (es) 2012-10-12

Family

ID=43735019

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001547A CL2012001547A1 (es) 2009-12-10 2012-06-08 Anticuerpo ligante de csf-1r humano; composicion farmaceutica que lo comprende; acido nucleico que lo codifica; vector de expresion recombinante; celula procariotica o eucariotica transformada; metodo de produccion; y su uso para tratar cancer.

Country Status (36)

Country Link
US (10) US8999327B2 (es)
EP (2) EP2949670B1 (es)
JP (3) JP5677451B2 (es)
KR (1) KR101434070B1 (es)
CN (2) CN105218672A (es)
AR (1) AR079333A1 (es)
AU (2) AU2010329934B2 (es)
BR (1) BR112012013717B1 (es)
CA (1) CA2780692C (es)
CL (1) CL2012001547A1 (es)
CO (1) CO6541621A2 (es)
CR (1) CR20120215A (es)
CY (1) CY1117331T1 (es)
DK (2) DK2510010T3 (es)
EC (1) ECSP12011964A (es)
ES (2) ES2722300T3 (es)
HK (1) HK1219739A1 (es)
HR (2) HRP20160131T1 (es)
HU (2) HUE026201T2 (es)
IL (1) IL219595A (es)
LT (1) LT2949670T (es)
MA (1) MA34780B1 (es)
MX (2) MX2012006553A (es)
MY (1) MY159679A (es)
NZ (1) NZ599516A (es)
PE (1) PE20121398A1 (es)
PH (1) PH12012500881A1 (es)
PL (2) PL2949670T3 (es)
PT (2) PT2949670T (es)
RS (2) RS54596B1 (es)
RU (1) RU2565541C2 (es)
SG (1) SG181589A1 (es)
SI (2) SI2949670T1 (es)
TW (1) TWI422388B (es)
WO (1) WO2011070024A1 (es)
ZA (1) ZA201203782B (es)

Families Citing this family (277)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE026201T2 (en) 2009-12-10 2016-05-30 Hoffmann La Roche Antibodies binding to human CSF1R extracellular domain 4 and their use
EP2542587A1 (en) 2010-03-05 2013-01-09 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
WO2011131407A1 (en) 2010-03-05 2011-10-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
SG185035A1 (en) 2010-05-04 2012-11-29 Five Prime Therapeutics Inc Antibodies that bind csf1r
ES2618828T3 (es) 2011-07-18 2017-06-22 The University Of Melbourne Uso de antagonistas de c-Fms
JP6005751B2 (ja) * 2011-10-21 2016-10-12 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． マクロファージの活性化の調節
US10023643B2 (en) 2011-12-15 2018-07-17 Hoffmann-La Roche Inc. Antibodies against human CSF-1R and uses thereof
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
JP2015517490A (ja) * 2012-05-11 2015-06-22 ファイブ プライム セラピューティックス インコーポレイテッド コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2014036357A1 (en) 2012-08-31 2014-03-06 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CA2884704C (en) 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
TWI539961B (zh) * 2012-11-09 2016-07-01 轉殖基因公司 單核球或其前驅細胞分化之調節
WO2014167088A1 (en) 2013-04-12 2014-10-16 Morphosys Ag Antibodies targeting m-csf
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
AR097584A1 (es) * 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
AU2014369982B2 (en) 2013-12-24 2019-04-18 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
AU2014372309C1 (en) * 2013-12-24 2017-12-14 Janssen Pharmaceutica Nv Anti-VISTA antibodies and fragments
PT3151921T (pt) 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
CN106535884A (zh) 2014-06-06 2017-03-22 弗雷克萨斯生物科学公司 免疫调节剂
SG11201610672YA (en) 2014-06-23 2017-01-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
RS61853B1 (sr) 2014-10-29 2021-06-30 Bicyclerd Ltd Biciklični peptidni ligandi specifični za mt1-mmp
WO2016069727A1 (en) 2014-10-29 2016-05-06 Five Prime Therapeutics, Inc. Combination therapy for cancer
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
MX2017005462A (es) 2014-11-05 2017-07-28 Flexus Biosciences Inc Agentes inmunorreguladores.
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
UY36404A (es) 2014-11-21 2016-06-01 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware ANTICUERPOS MONOCLONALES (Ab) COMO DETECTORES DE CD73 E INHIBIDORES DE SU ACTIVIDAD ENZIMÁTICA, Y COMPOSICIONES QUE LOS CONTIENEN
TW201630907A (zh) 2014-12-22 2016-09-01 必治妥美雅史谷比公司 ＴＧＦβＲ拮抗劑
WO2016106180A1 (en) 2014-12-22 2016-06-30 Five Prime Therapeutics, Inc. Anti-csf1r antibodies for treating pvns
US10189902B2 (en) 2014-12-23 2019-01-29 Bristol-Myers Squibb Company Antibodies to TIGIT
WO2016127052A1 (en) 2015-02-05 2016-08-11 Bristol-Myers Squibb Company Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
ES2789331T3 (es) 2015-03-02 2020-10-26 Rigel Pharmaceuticals Inc Inhibidores de TGF-beta
EA201792186A1 (ru) 2015-04-03 2018-03-30 Бристол-Майерс Сквибб Компани Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
WO2016162505A1 (en) 2015-04-08 2016-10-13 F-Star Biotechnology Limited Her2 binding agent therapies
PL3283527T3 (pl) 2015-04-13 2021-06-14 Five Prime Therapeutics, Inc. Leczenie skojarzone nowotworów
US10683290B2 (en) 2015-05-11 2020-06-16 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
WO2016183115A1 (en) 2015-05-12 2016-11-17 Bristol-Myers Squibb Company 5h-pyrido[3,2-b]indole compounds as anticancer agents
AU2016263808B2 (en) 2015-05-21 2019-01-03 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
WO2016196228A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
EP3108897A1 (en) 2015-06-24 2016-12-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
KR20180012873A (ko) * 2015-06-24 2018-02-06 에프. 호프만-라 로슈 아게 림프종 또는 백혈병에서 림프구증가증의 유도에 사용하기 위한 인간 csf-1r에 대한 항체
UY36757A (es) 2015-06-29 2016-12-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
KR20180034548A (ko) 2015-07-28 2018-04-04 브리스톨-마이어스 스큅 컴퍼니 Tgf 베타 수용체 길항제
JP2018525415A (ja) 2015-08-25 2018-09-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｇｆベータ受容体アンタゴニスト
HK1255056A1 (zh) * 2015-09-16 2019-08-02 Ablexis, Llc 抗cd115抗体
US10584160B2 (en) 2015-09-23 2020-03-10 Bristol-Myers Squibb Company Glypican-3-binding fibronectin based scaffold molecules
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
CN108602829A (zh) 2015-12-15 2018-09-28 百时美施贵宝公司 Cxcr4受体拮抗剂
CA3016187A1 (en) 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
KR20230119259A (ko) 2016-04-15 2023-08-16 이뮤넥스트, 인크. 항-인간 vista 항체 및 이의 용도
EP3445783A2 (en) 2016-04-18 2019-02-27 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
CN105820250B (zh) 2016-04-29 2019-04-30 中国人民解放军第四军医大学 一种抗basigin人源化抗体及其应用
EP3452451A4 (en) 2016-05-04 2019-11-13 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
KR20190004743A (ko) 2016-05-04 2019-01-14 브리스톨-마이어스 스큅 컴퍼니 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
WO2017192840A1 (en) 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10696648B2 (en) 2016-05-04 2020-06-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
JP2019516682A (ja) 2016-05-04 2019-06-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
JP6683020B2 (ja) 2016-06-01 2020-04-15 株式会社デンソー 電力変換装置、及び、これを用いた電動パワーステアリング装置
BR112018076281A2 (pt) 2016-06-20 2019-03-26 Kymab Limited imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo
BR112019000431A2 (pt) 2016-07-14 2019-07-09 Bristol-Myers Squibb Company anticorpos contra tim3 e usos dos mesmos
US20190292179A1 (en) 2016-07-21 2019-09-26 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
CN109790220A (zh) 2016-08-25 2019-05-21 豪夫迈·罗氏有限公司 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
JP2019528301A (ja) 2016-08-26 2019-10-10 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ インドールアミン２，３−ジオキシゲナーゼの阻害剤およびその使用方法
WO2018039518A1 (en) 2016-08-26 2018-03-01 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
JP2018047147A (ja) * 2016-09-23 2018-03-29 株式会社三共 スロットマシン
JP2018047146A (ja) * 2016-09-23 2018-03-29 株式会社三共 スロットマシン
JP2018047145A (ja) * 2016-09-23 2018-03-29 株式会社三共 スロットマシン
JP2018047144A (ja) * 2016-09-23 2018-03-29 株式会社三共 スロットマシン
JP2018061577A (ja) * 2016-10-11 2018-04-19 株式会社三共 スロットマシン
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
JP7304287B2 (ja) 2016-12-22 2023-07-06 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
US10961239B2 (en) 2017-01-05 2021-03-30 Bristol-Myers Squibb Company TGF beta receptor antagonists
ES2971271T3 (es) 2017-01-20 2024-06-04 Arcus Biosciences Inc Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer
WO2018183366A1 (en) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
US12134654B2 (en) 2017-04-19 2024-11-05 Marengo Therapeutics, Inc. Multispecific molecules and uses thereof
CN110831600B (zh) 2017-04-21 2023-10-17 医肯纳肿瘤学公司 吲哚ahr抑制剂和其用途
CN110891974B (zh) 2017-05-12 2021-08-06 哈普恩治疗公司 间皮素结合蛋白质
US11066392B2 (en) 2017-05-12 2021-07-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
ES2951809T3 (es) 2017-05-17 2023-10-25 Arcus Biosciences Inc Derivados de quinazolina-pirazol para el tratamiento de trastornos relacionados con el cáncer
CN111278459A (zh) 2017-05-19 2020-06-12 赛达克斯制药股份有限公司 组合疗法
US11236049B2 (en) 2017-06-30 2022-02-01 Bristol-Myers Squibb Company Amorphous and crystalline forms of IDO inhibitors
ES2932354T3 (es) 2017-07-28 2023-01-18 Bristol Myers Squibb Co Dinucleótidos cíclicos como agentes anticáncer
CN111183147B (zh) 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
BR112020003116A2 (pt) 2017-08-17 2020-08-04 Ikena Oncology, Inc. inibidores de ahr e usos dos mesmos
ES2904317T3 (es) 2017-08-31 2022-04-04 Bristol Myers Squibb Co Dinucleótidos cíclicos como agentes anticancerosos
US11667663B2 (en) 2017-08-31 2023-06-06 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
KR102651946B1 (ko) 2017-08-31 2024-03-26 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
EP3681535A1 (en) 2017-09-13 2020-07-22 Five Prime Therapeutics, Inc. Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
IL273432B (en) 2017-09-22 2022-09-01 Kymera Therapeutics Inc Protein compounds and their uses
US11649212B2 (en) 2017-10-09 2023-05-16 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019074824A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
KR102885797B1 (ko) 2017-10-10 2025-11-12 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
CR20200196A (es) 2017-10-13 2020-06-05 Harpoon Therapeutics Inc Proteínas trispecìficas y mètodos de uso
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
WO2019079261A1 (en) 2017-10-16 2019-04-25 Bristol-Myers Squibb Company CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
KR20200074214A (ko) 2017-11-01 2020-06-24 브리스톨-마이어스 스큅 컴퍼니 암을 치료하는데 사용하기 위한 면역자극 효능작용 항체
ES2925450T3 (es) 2017-11-06 2022-10-18 Bristol Myers Squibb Co Compuestos de isofuranona útiles como inhibidores de HPK1
WO2019106097A1 (en) 2017-11-30 2019-06-06 F.Hoffmann-La Roche Ag Process for culturing mammalian cells
EP3720881A1 (en) 2017-12-08 2020-10-14 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
EP3732198A1 (en) 2017-12-27 2020-11-04 Bristol-Myers Squibb Company Anti-cd40 antibodies and uses thereof
WO2019136112A1 (en) 2018-01-05 2019-07-11 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN111886255B (zh) 2018-01-12 2025-04-04 百时美施贵宝公司 抗tim3抗体及其用途
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
CN108276495B (zh) * 2018-01-24 2022-03-18 博生吉医药科技(苏州)有限公司 靶向csf1r嵌合抗原受体修饰的nk92mi细胞和t细胞及其制法和应用
WO2019147982A1 (en) 2018-01-26 2019-08-01 Celldex Therapeutics, Inc. Methods of treating cancer with dendritic cell mobilizing agents
SG11202006832YA (en) 2018-01-29 2020-08-28 Merck Patent Gmbh Gcn2 inhibitors and uses thereof
KR20200116481A (ko) 2018-01-29 2020-10-12 메르크 파텐트 게엠베하 Gcn2 억제제 및 이의 용도
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
US11478479B2 (en) 2018-02-16 2022-10-25 Arcus Biosciences, Inc. Dosing with an azolopyrimidine compound
CA3091775A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
JP7463281B2 (ja) * 2018-03-05 2024-04-08 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド コロニー刺激因子を標的とすることによる、緑内障および視神経症のための療法
SG11202008113RA (en) 2018-03-05 2020-09-29 Arcus Biosciences Inc Arginase inhibitors
JP7250808B2 (ja) 2018-03-08 2023-04-03 ブリストル－マイヤーズ スクイブ カンパニー 抗がん剤としての環状ジヌクレオチド
TW201945393A (zh) 2018-03-21 2019-12-01 美商戊瑞治療有限公司 在酸性pH結合至VISTA之抗體
CA3093407A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
PE20210313A1 (es) 2018-03-28 2021-02-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
JP2021521182A (ja) 2018-04-12 2021-08-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３アンタゴニストとｐｄ−１／ｐｄ−ｌ１軸アンタゴニストの組み合わせ治療
CA3096546A1 (en) 2018-04-16 2019-10-24 Arrys Therapeutics, Inc. Ep4 inhibitors and use thereof
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
SI3814348T1 (sl) 2018-06-27 2023-10-30 Bristol-Myers Squibb Company Substituirane naftiridinonske spojine, uporabne kot aktivatorji t celic
HRP20230627T1 (hr) 2018-06-27 2023-09-29 Bristol-Myers Squibb Company Spojevi naftiridinona korisni kao aktivatori t ćelija
EP3817822A4 (en) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
EP3817748A4 (en) 2018-07-06 2022-08-24 Kymera Therapeutics, Inc. TRICYCLIC CRBN LIGANDS AND USES THEREOF
SG11202100096XA (en) 2018-07-09 2021-02-25 Five Prime Therapeutics Inc Antibodies binding to ilt4
CN121203021A (zh) 2018-07-11 2025-12-26 戊瑞治疗有限公司 在酸性pH下结合至VISTA的抗体
AU2019306582B2 (en) 2018-07-18 2023-03-16 Arcus Biosciences, Inc. Solid forms of an azolopyrimidine compound
CN109096397B (zh) * 2018-07-18 2019-04-16 博奥信生物技术（南京）有限公司 一种抗人csf-1r单克隆抗体及应用
WO2020023355A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US12145927B2 (en) 2018-07-23 2024-11-19 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10959986B2 (en) 2018-08-29 2021-03-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11253525B2 (en) 2018-08-29 2022-02-22 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US12030875B2 (en) 2018-09-07 2024-07-09 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
CN118356487A (zh) 2018-09-13 2024-07-19 豪夫迈·罗氏有限公司 Csf-1r抗体制剂
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
WO2020069028A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
AU2019346645A1 (en) 2018-09-27 2021-04-29 Marengo Therapeutics, Inc. CSF1R/CCR2 multispecific antibodies
WO2020076969A2 (en) 2018-10-10 2020-04-16 Tilos Therapeutics, Inc. Anti-lap antibody variants and uses thereof
CA3120196A1 (en) 2018-11-16 2020-05-22 Arcus Biosciences, Inc. Inhibitors of arg1 and/or arg2
AU2019380307B2 (en) 2018-11-16 2026-01-29 Bristol-Myers Squibb Company Anti-NKG2A antibodies and uses thereof
AU2019389174A1 (en) 2018-11-30 2021-07-01 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US20220016168A1 (en) 2018-12-11 2022-01-20 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
JP2022514618A (ja) 2018-12-21 2022-02-14 バイスクルテクス・リミテッド Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
KR20210137162A (ko) 2019-03-12 2021-11-17 아르커스 바이오사이언시즈 인코포레이티드 종양유전자-유발 암의 치료
AU2020242284A1 (en) 2019-03-19 2021-09-16 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy for the treatment of cancer
US12310965B2 (en) 2019-03-29 2025-05-27 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
US20220184222A1 (en) 2019-04-02 2022-06-16 Bicycletx Limited Bicycle toxin conjugates and uses thereof
CA3135802A1 (en) 2019-04-05 2020-10-08 Kymera Therapeutics, Inc. Stat degraders and uses thereof
WO2020231713A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2020231766A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
EP3976192A1 (en) 2019-05-31 2022-04-06 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
CN114502158A (zh) 2019-06-28 2022-05-13 凯麦拉医疗公司 Irak降解剂及其用途
US20220306630A1 (en) 2019-08-06 2022-09-29 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
US12215105B2 (en) 2019-09-13 2025-02-04 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
AU2020350689A1 (en) 2019-09-19 2022-03-31 Bristol-Myers Squibb Company Antibodies binding to VISTA at acidic pH
EP4034558A1 (en) 2019-09-26 2022-08-03 Roche Diagnostics GmbH Anti-csf-1r antibody
WO2021087105A1 (en) 2019-10-30 2021-05-06 Duke University Immunotherapy with combination therapy comprising an immunotoxin
JP7629459B2 (ja) 2019-11-19 2025-02-13 ブリストル－マイヤーズ スクイブ カンパニー Ｈｅｌｉｏｓタンパク質の阻害剤として有用な化合物
FI4065582T3 (fi) 2019-11-26 2025-05-25 Ikena Oncology Inc Polymorfisia karbatsolijohdannaisia ja niiden käyttötapoja
CN115151306A (zh) 2019-11-26 2022-10-04 百时美施贵宝公司 (r)-n-(4-氯苯基)-2-((1s，4s)-4-(6-氟喹啉-4-基)环己基)丙酰胺的盐/共晶
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
BR112022011651A2 (pt) 2019-12-17 2022-08-23 Kymera Therapeutics Inc Degradadores de irak e usos dos mesmos
BR112022012222A2 (pt) 2019-12-23 2022-09-13 Bristol Myers Squibb Co Derivados de piperazina substituídos úteis como ativadores de células t
ES3013568T3 (en) 2019-12-23 2025-04-14 Bristol Myers Squibb Co Substituted heteroaryl compounds useful as t cell activators
CA3162502A1 (en) 2019-12-23 2021-07-01 Yi Zhang Smarca degraders and uses thereof
IL294269A (en) 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted quinolinonyl piperazine compounds useful as t cell activators
US12492172B2 (en) 2019-12-23 2025-12-09 Bristol-Myers Squibb Company Substituted quinazolinyl compounds useful as T cell activators
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
TWI844756B (zh) * 2019-12-24 2024-06-11 大陸商寶船生物醫藥科技（上海）有限公司 抗ｃｓｆ１ｒ分子及其用途
WO2021139682A1 (en) 2020-01-07 2021-07-15 Hifibio (Hk) Limited Anti-galectin-9 antibody and uses thereof
EP4114529A1 (en) 2020-03-03 2023-01-11 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
JP2023516459A (ja) 2020-03-09 2023-04-19 ブリストル－マイヤーズ スクイブ カンパニー 増強されたアゴニスト活性を有するｃｄ４０に対する抗体
EP4121043A4 (en) 2020-03-19 2024-07-24 Kymera Therapeutics, Inc. Mdm2 degraders and uses thereof
EP4121409A1 (en) 2020-03-19 2023-01-25 Arcus Biosciences, Inc. Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
TW202140441A (zh) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
GB202005274D0 (en) * 2020-04-09 2020-05-27 Univ Surrey Monocyte
EP4132971A1 (en) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinity matured anti-lap antibodies and uses thereof
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
TW202210514A (zh) 2020-06-02 2022-03-16 美商阿克思生物科學有限公司 針對tigit的抗體
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
WO2021247897A1 (en) 2020-06-03 2021-12-09 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
JP2023530456A (ja) 2020-06-17 2023-07-18 アーカス バイオサイエンシズ インコーポレイティド Ｃｄ７３阻害剤の結晶形態及びその使用
JP2023532768A (ja) 2020-07-07 2023-07-31 バイオエヌテック エスエー Ｈｐｖ陽性癌の治療用ｒｎａ
JP2023536462A (ja) 2020-07-30 2023-08-25 カイメラ セラピューティクス， インコーポレイテッド 変異体リンパ腫を処置する方法
CN116348476A (zh) 2020-08-03 2023-06-27 拜斯科技术开发有限公司 基于肽的接头
AU2021327130A1 (en) 2020-08-17 2023-03-02 Bicycletx Limited Bicycle conjugates specific for Nectin-4 and uses thereof
EP4255895A1 (en) 2020-12-02 2023-10-11 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
CA3202360A1 (en) 2020-12-30 2022-07-07 Nello Mainolfi Irak degraders and uses thereof
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
EP4288430A1 (en) 2021-02-02 2023-12-13 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
AU2022216810A1 (en) 2021-02-02 2023-08-24 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
WO2022169921A1 (en) 2021-02-04 2022-08-11 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
WO2022174253A1 (en) 2021-02-12 2022-08-18 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
KR20230145446A (ko) 2021-02-15 2023-10-17 카이메라 쎄라퓨틱스 인코포레이티드 Irak4 분해제 및 이의 용도
CA3207049A1 (en) 2021-02-15 2022-08-18 Jared Gollob Irak4 degraders and uses thereof
EP4301756A4 (en) 2021-03-05 2025-02-26 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND THEIR USES
WO2022197641A1 (en) 2021-03-15 2022-09-22 Rapt Therapeutics, Inc. 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
EP4313989A4 (en) 2021-03-29 2025-03-05 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND USES THEREOF
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
JP2024515545A (ja) 2021-04-05 2024-04-10 ブリストル－マイヤーズ スクイブ カンパニー がん治療のためのピリジニル置換オキソイソインドリン化合物
FI4320112T3 (fi) 2021-04-06 2025-07-25 Bristol Myers Squibb Co Pyridinyylisubstituoituja oksoisoindoliiniyhdisteitä
MX2023011933A (es) 2021-04-09 2024-01-05 Nimbus Clio Inc Moduladores del linfoma de linaje b de casitas de ligasa e3 b (cbl-b) y usos de estos.
EP4323066A1 (en) 2021-04-16 2024-02-21 Ikena Oncology, Inc. Mek inhibitors and uses thereof
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
JP2024521706A (ja) 2021-05-21 2024-06-04 アーカス バイオサイエンシーズ，インコーポレーテッド Ａｘｌ化合物
JP2024521712A (ja) 2021-05-21 2024-06-04 アーカス バイオサイエンシーズ，インコーポレーテッド Ａｘｌ阻害化合物
JP2024525758A (ja) 2021-07-13 2024-07-12 ビオンテック・ソシエタス・エウロパエア がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
AU2022327766A1 (en) 2021-08-13 2023-12-14 Ludwig-Maximilians-Universität München Anti-csf1r car expressing lymphocytes for targeted tumor therapy
CN118103368A (zh) 2021-08-25 2024-05-28 皮克医疗公司 Eif4e抑制剂及其用途
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
MX2024005138A (es) 2021-10-29 2024-05-13 Kymera Therapeutics Inc Degradadores de cinasa-4 asociada al receptor de la interleucina-1 (irak-4) y sintesis de los mismos.
KR20240110814A (ko) 2021-10-29 2024-07-16 아르커스 바이오사이언시즈 인코포레이티드 Hif-2알파의 저해제 및 이의 사용 방법
US12454573B2 (en) * 2021-11-02 2025-10-28 Synox Therapeutics UK Limited Dosages of emactuzumab
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
US12091411B2 (en) 2022-01-31 2024-09-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
EP4472963A1 (en) 2022-02-01 2024-12-11 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
EP4518895A1 (en) 2022-05-02 2025-03-12 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same
WO2023230205A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof
US20240124490A1 (en) 2022-07-15 2024-04-18 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
EP4558501A1 (en) 2022-07-20 2025-05-28 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
JP2025527248A (ja) 2022-08-02 2025-08-20 リミナル・バイオサイエンシーズ・リミテッド 置換ピリドンｇｐｒ８４アンタゴニスト及びその使用
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
CN120019047A (zh) 2022-08-02 2025-05-16 里米诺生物科学有限公司 杂芳基甲酰胺和相关gpr84拮抗剂及其用途
KR20250046309A (ko) 2022-08-08 2025-04-02 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 테트라졸릴 화합물
JP2025528157A (ja) 2022-08-09 2025-08-26 ブリストル－マイヤーズ スクイブ カンパニー Ｔ細胞活性化剤として有用な第三アミン置換二環式化合物
WO2024081385A1 (en) 2022-10-14 2024-04-18 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
CN120091809A (zh) 2022-10-20 2025-06-03 艾库斯生物科学有限公司 Cd73化合物的冻干制剂
US20240208961A1 (en) 2022-11-22 2024-06-27 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
WO2024156672A1 (en) 2023-01-25 2024-08-02 F. Hoffmann-La Roche Ag Antibodies binding to csf1r and cd3
US20240425497A1 (en) 2023-05-05 2024-12-26 Arcus Biosciences, Inc. Cbl-b Inhibitors and Methods of Use Thereof
CN121057732A (zh) 2023-05-08 2025-12-02 百时美施贵宝公司 经取代的苯基噁唑酮化合物
CN121219009A (zh) 2023-05-17 2025-12-26 信达克思制药公司 使用抗集落刺激因子1受体抗体治疗慢性移植物抗宿主病相关的闭塞性细支气管炎综合征的方法
WO2024243502A1 (en) 2023-05-25 2024-11-28 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
CN121368591A (zh) 2023-05-31 2026-01-20 百时美施贵宝公司 用于降低ikzf 1-4蛋白水平的经取代的噁唑酮化合物
CN121487946A (zh) 2023-06-07 2026-02-06 百时美施贵宝公司 螺环取代的氧代异吲哚啉基哌啶-2,6-二酮化合物
US20250059164A1 (en) 2023-06-23 2025-02-20 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2025030002A2 (en) 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2025064197A1 (en) 2023-09-02 2025-03-27 Bristol-Myers Squibb Company Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
AR133696A1 (es) 2023-09-02 2025-10-22 Bristol Myers Squibb Co Compuestos de fenil oxooxazolil piperidinadiona sustituida
KR20250068738A (ko) 2023-09-13 2025-05-16 브리스톨-마이어스 스큅 컴퍼니 치환된 옥소이소인돌리닐 피페리딘-2,6-디온 화합물
TW202517260A (zh) 2023-10-06 2025-05-01 美商阿克思生物科學有限公司 Ｃｂｌ—ｂ抑制劑及其使用方法
TW202535865A (zh) 2023-10-31 2025-09-16 美商必治妥美雅史谷比公司 泛素特異性加工蛋白酶1 (usp1) 化合物
WO2025096505A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096489A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096494A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096487A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096488A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
TW202541837A (zh) 2023-12-08 2025-11-01 日商安斯泰來製藥公司 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025226767A1 (en) 2024-04-24 2025-10-30 Bristol-Myers Squibb Company Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
WO2026006759A1 (en) 2024-06-28 2026-01-02 Arcus Biosciences, Inc. Pharmaceutical compositions, dosage forms, and methods of making and using same

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5606040A (en) * 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) * 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
ATE195553T1 (de) 1992-06-09 2000-09-15 Chiron Corp Kristallisierung von m-csf
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5635483A (en) * 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) * 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
JPH0967400A (ja) 1995-08-31 1997-03-11 Toray Ind Inc モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用
IL130864A0 (en) 1997-03-03 2001-01-28 Bristol Myers Squibb Co Monoclonal antibodies to human cd6
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
JP4891477B2 (ja) 1997-10-02 2012-03-07 マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー．ヴェー． 血管新生及び／または既存細動脈網から側枝動脈及び／または他の動脈の発達の調節に関する方法
WO2001030381A2 (de) 1999-10-28 2001-05-03 Hofbauer, Reinhold Verwendung von csf-1-inhibitoren
NZ518764A (en) * 1999-12-29 2004-02-27 Immunogen Inc Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
SI1572106T1 (sl) 2002-11-15 2010-08-31 Novartis Vaccines & Diagnostic Postopki za preprečevanje in zdravljenje rakavih metastaz in izgube kosti, povezane z rakavimi metastazami
GB0325836D0 (en) 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
PT1725249E (pt) * 2003-11-06 2014-04-10 Seattle Genetics Inc Compostos de monometilvalina capazes de conjugação a ligandos
WO2006012451A2 (en) 2004-07-22 2006-02-02 Five Prime Therapeutics, Inc. Compositions and methods of use for mgd-csf in disease treatment
JP2006249082A (ja) 2005-03-08 2006-09-21 Pharmacia & Upjohn Co Llc 低減レベルの内毒素を有する抗ｍ−ｃｓｆ抗体組成物
CA2632698A1 (en) 2005-12-09 2007-07-05 Seattle Genetics, Inc. Methods of using cd40 binding agents
KR20080083187A (ko) 2006-01-05 2008-09-16 노바르티스아게 암 전이 및 암 전이와 관련된 골 소실의 예방 및 치료 방법
US20070280935A1 (en) 2006-04-07 2007-12-06 Bernd Bohrmann Antibody that recognizes phosphorylated peptides
US7884197B2 (en) 2006-12-12 2011-02-08 Idera Pharmaceuticals, Inc. Synthetic agonists of TLR9
CA2681790A1 (en) 2007-03-30 2008-10-09 F. Hoffmann-La Roche Ag Composition of labeled and non-labeled monoclonal antibodies
BRPI0812400A2 (pt) 2007-06-05 2014-10-29 Univ Yale Unidade, hibridoma, composição farmacêutica, método para identificar uma unidade, anticorpo isolado a uma unidade de ligação de antígeno do mesmo, molécula peptídica, e, uso da unidade.
EA023555B1 (ru) 2007-08-21 2016-06-30 Амген Инк. АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ c-fms ЧЕЛОВЕКА
CN101970496B (zh) 2008-03-14 2014-04-16 特朗斯吉有限公司 针对csf-1r的抗体
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
US8709715B2 (en) 2008-03-26 2014-04-29 Cellerant Therapeutics, Inc. Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
BRPI0917592B1 (pt) 2008-12-09 2021-08-17 Genentech, Inc Anticorpo anti-pd-l1, composição, artigos manufaturados e usos de uma composição
JP5694921B2 (ja) 2009-04-20 2015-04-01 協和発酵キリン株式会社 アミノ酸変異が導入されたＩｇＧ２を有する抗体
RS60033B1 (sr) 2009-11-24 2020-04-30 Medimmune Ltd Ciljano vezujući agensi usmereni na b7-h1
HUE026201T2 (en) 2009-12-10 2016-05-30 Hoffmann La Roche Antibodies binding to human CSF1R extracellular domain 4 and their use
EP2542587A1 (en) 2010-03-05 2013-01-09 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
WO2011131407A1 (en) 2010-03-05 2011-10-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
SG185035A1 (en) * 2010-05-04 2012-11-29 Five Prime Therapeutics Inc Antibodies that bind csf1r
JP5798404B2 (ja) 2010-08-31 2015-10-21 日東電工株式会社 極板保護用粘着テープ
ES2618828T3 (es) 2011-07-18 2017-06-22 The University Of Melbourne Uso de antagonistas de c-Fms
JP6005751B2 (ja) 2011-10-21 2016-10-12 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． マクロファージの活性化の調節
US10023643B2 (en) 2011-12-15 2018-07-17 Hoffmann-La Roche Inc. Antibodies against human CSF-1R and uses thereof
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
JP2015517490A (ja) 2012-05-11 2015-06-22 ファイブ プライム セラピューティックス インコーポレイテッド コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法
MY171307A (en) 2012-07-24 2019-10-08 Hitachi Metals Ltd Target material and method of producing the same
WO2014036357A1 (en) 2012-08-31 2014-03-06 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
TWI539961B (zh) 2012-11-09 2016-07-01 轉殖基因公司 單核球或其前驅細胞分化之調節
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano

Also Published As

Publication number Publication date
KR20120098872A (ko) 2012-09-05
EP2949670A1 (en) 2015-12-02
US20190071507A1 (en) 2019-03-07
CN102791738B (zh) 2015-10-07
BR112012013717A2 (pt) 2017-01-10
JP2017123850A (ja) 2017-07-20
ECSP12011964A (es) 2012-07-31
AU2010329934A1 (en) 2012-05-17
RU2565541C2 (ru) 2015-10-20
LT2949670T (lt) 2019-05-27
CN102791738A (zh) 2012-11-21
US20190300614A1 (en) 2019-10-03
SG181589A1 (en) 2012-07-30
US20170029517A1 (en) 2017-02-02
MA34780B1 (fr) 2014-01-02
US20150274831A1 (en) 2015-10-01
PH12012500881A1 (en) 2017-07-26
ES2722300T3 (es) 2019-08-09
TWI422388B (zh) 2014-01-11
US20180244788A1 (en) 2018-08-30
KR101434070B1 (ko) 2014-08-25
PE20121398A1 (es) 2012-10-26
TW201129381A (en) 2011-09-01
RU2012128651A (ru) 2014-01-20
PL2949670T3 (pl) 2019-07-31
AU2010329934B2 (en) 2015-05-14
MY159679A (en) 2017-01-13
PL2510010T3 (pl) 2016-05-31
MX2012006553A (es) 2012-08-03
EP2949670B1 (en) 2019-02-27
JP2015120697A (ja) 2015-07-02
AR079333A1 (es) 2012-01-18
CA2780692C (en) 2018-09-11
US9879085B2 (en) 2018-01-30
ZA201203782B (en) 2017-01-25
WO2011070024A1 (en) 2011-06-16
PT2949670T (pt) 2019-05-20
US9499624B2 (en) 2016-11-22
US10077314B1 (en) 2018-09-18
HK1219739A1 (zh) 2017-04-13
HRP20190762T1 (hr) 2019-06-28
US20150274830A1 (en) 2015-10-01
PT2510010E (pt) 2016-01-11
CN105218672A (zh) 2016-01-06
BR112012013717B1 (pt) 2020-01-28
US20180208662A1 (en) 2018-07-26
US10287358B2 (en) 2019-05-14
EP2510010B1 (en) 2015-11-25
US20150158950A1 (en) 2015-06-11
BR112012013717A8 (pt) 2017-12-26
US8999327B2 (en) 2015-04-07
RS54596B1 (sr) 2016-08-31
NZ599516A (en) 2013-11-29
RS58693B1 (sr) 2019-06-28
IL219595A (en) 2017-03-30
EP2510010A1 (en) 2012-10-17
US9663580B2 (en) 2017-05-30
MX353706B (es) 2018-01-24
DK2510010T3 (en) 2015-12-14
US9499625B2 (en) 2016-11-22
HUE044179T2 (hu) 2019-10-28
HRP20160131T1 (hr) 2016-03-11
HUE026201T2 (en) 2016-05-30
CO6541621A2 (es) 2012-10-16
JP5677451B2 (ja) 2015-02-25
US10072087B2 (en) 2018-09-11
DK2949670T3 (da) 2019-05-13
ES2557454T3 (es) 2016-01-26
US20110165156A1 (en) 2011-07-07
JP2013513367A (ja) 2013-04-22
HK1176361A1 (zh) 2013-07-26
CR20120215A (es) 2012-06-01
US9499626B2 (en) 2016-11-22
AU2015213308B2 (en) 2017-09-14
IL219595A0 (en) 2012-06-28
CY1117331T1 (el) 2017-04-26
CA2780692A1 (en) 2011-06-16
SI2510010T1 (sl) 2016-02-29
US20170320953A1 (en) 2017-11-09
SI2949670T1 (sl) 2019-05-31
AU2015213308A1 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
CL2012001547A1 (es) Anticuerpo ligante de csf-1r humano; composicion farmaceutica que lo comprende; acido nucleico que lo codifica; vector de expresion recombinante; celula procariotica o eucariotica transformada; metodo de produccion; y su uso para tratar cancer.
CL2012001649A1 (es) Anticuerpo de unión a her3/erb-3/c-erbb-3/c-erbb3 humano; acido nucleico que lo codifica; vector de expresión recombinante; célula huésped procariótica o eucariótica transformada que comprende dicho vector; método de producción de dicho anticuerpo; composición farmacéutica que lo comprende; y su uso para tratar cáncer.
CL2013000566A1 (es) Proteina de union a antigeno que une her3; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar cancer.
CL2013001625A1 (es) Proteina de union que se une especificamente a tnf-alfa; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar una enfermedad o trastorno asociado a tnf-alfa.
CL2011002611A1 (es) Anticuerpo aislado anti-cadherina-17; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; inmunoconjugado que lo comprende; composicion que lo comprende; y su uso para tratar o prevenir una enfermedad asociada con celulas objetivo que expresan cadherina-17.
CL2014000631A1 (es) Molecula de union que se une a cd134 (ox40); molecula de acido nucleico que la codifica; vector; celula huesped; proceso de preparacion; composicion farmaceutica que la comprende; y su uso para tratar cancer.
CL2013000545A1 (es) Anticuerpo anti-ox40; acido nucleico que lo codifica; celula huesped; metodo de produccion; y su uso para tratar cancer o una enfermedad autoinmune.
CL2007001488A1 (es) Anticuerpo humano o humanizado anti-integrina alfa5beta1; acido nucleico que lo codifica; vector y celula huesped que lo comprenden; procedimiento de produccion; composicion farmaceutica que lo comprende; y su uso para prevenir o tratar trastornos asociados con la integrina.
CL2013000074A1 (es) Proteina de union con capacidad de unir un par de antigenos; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; conjugado que comprende dicha proteina de union; y sus usos.
CL2013000369A1 (es) Anticuerpo que se une especificamente a la proteina de activacion fibroblastica (fap); polinucleotido que lo codifica; vector; celula huesped; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar cancer.
CL2014001055A1 (es) Proteina de union biespecifica que se enlaza al factor de necrosis tumoral (tnf) y la interleucina 17 (il-17); acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso.
CL2007002987A1 (es) Anticuerpos anti-notch3; acido nucleico que los codifica; vector y celula que lo comprende; metodo de produccion; y su uso para tratar enfermedades relacionadas con notch3.
CL2011000672A1 (es) Anticuerpo que se une a il-17 humana; acido nucleico que lo codifica; vector de expresion; linea celular; metodo de produccion; composicion farmaceutica que lo comprende y su uso para tratar artritis reumatoidea entre otras enfermedades.
CL2011002784A1 (es) Anticuerpo anti-egfl7; acido nucleico que lo codifica; vector; celula huesped; metodo de preparacion; composicion que lo comprende, y su uso para tratar un tumor, cancer o un trastorno proliferativo.
CL2011001285A1 (es) Anticuerpo que se une a la angiopoyetina-2 humana (ang-2 o ang2 o angpt2); acido nucleico que lo codifica; vector de expresion recombinante; celula huesped; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
CL2013001279A1 (es) Anticuerpo humano aislado o fragmento de union a antigeno del mismo que se une especificamente y neutraliza la actividad del ligando 1a de tipo tnf humano (htl1a); molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso.
CL2011002039A1 (es) Anticuerpo humanizado que se une al cd19 humano; acido nucleico aislado que codifica dicho anticuerpo; vector y celula huesped; composicion e inmunoconjugado; metodo para inhibir el crecimiento de celulas de tumor que expresan cd19.
CL2013003336A1 (es) Anticuerpo anti-cgrp humano; acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica y diagnostica que lo comprende; y su uso terapéutico
CL2007003623A1 (es) Proteina de enlace multivalente monocatenaria con funcion efectora; acido nucleico que la codifica; vector y celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y metodo para tratar trastornos proliferativos.
CL2014000958A1 (es) Polipeptidos de anticuerpos que antagonizan cd4ol; acido nucleico que codifica dicho anticuerpo; vector y célula huesped que la comprenden; composicion farmacéutica; uso de dichos polipéptidos para tratar enfermedad inmunitaria.
CL2011002482A1 (es) Anticuerpo biespecificos que se une especificamente a las proteinas erbb-3 humana y c-met humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar cancer
CL2015003090A1 (es) Proteínas de unión específicas y sus usos.
CL2007003357A1 (es) Anticuerpo o fragmento funcional del mismo capaz de inhibir la proliferacion de celulas tumorales in vitro y/o in vivo; acido nucleico que lo codifica; metodo de produccion; composicion que lo comprende; y su uso para tratar el cancer.
BR112014004168A2 (pt) anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção
CL2009000166A1 (es) Polipeptido de fusion que comprende un subdominio de la proteina klotho y el factor de crecimiento de fibroblastos; composicion farmaceutica que contiene el polipeptido; acido nucleico; vector y celula huesped que lo contiene; uso de esta composicion para tratar condiciones mediadas por el envejecimiento.